UbiVac and Janssen form collaboration

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

UbiVac formed a collaboration with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop new preclinical and clinical versions of UbiVac’s proprietary DRibble immunotherapy for use in preclinical studies of oral cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Throughout my career as a physician and scientist, I’ve seen ideas once considered impossible become breakthroughs that save lives. They happened because talented scientists had the resources, institutions, and sustained support to pursue ambitious ideas. Most importantly, they knew patients could not afford to wait. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login